Back
Return
Biography
Sébastien Fortin

Dr. Sébastien Fortin

Faculty of Pharmacy

Université Laval, Canada

CHU de Québec Research Center, Canada

Assistant professor


Email: sebastien.fortin@pha.ulaval.ca


Qualifications

2010 Ph.D., Medicinal Chemistry, Université Laval, Canada

2010 Ph.D., Medicinal Chemistry, Université d’Auvergne 1, France

2005 M.Sc., Medicinal Chemistry, Université Laval, Canada

2003 B.Sc., Chemistry, Université Laval


Publications

  1. Gagné-Boulet M., Fortin S., Lacroix J., Lefebvre C.-A., Côté M.-F. et C.-Gaudreault R. (2015), Styryl-N-phenyl-N'-(2-chloroethyl)ureas and styrylphenylimidazolidin-2-ones as new potent microtubule-disrupting agents using combretastatin A-4 as model, European Journal of Medicinal Chemistry, 100, 34-43.
  2. Fortin S., Wei L., P. Kotra L. and C.-Gaudreault R. (2015), Novel cytocidal substituted phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates and benzenesulfonamides with affinity to the colchicine-binding site: is the phenyl 2-imidazolidinone moiety a new haptophore for the design of new antimitotics?, Open Journal of Medicinal Chemistry, 5, 9-22.
  3. Morin N., Bruneau J., Fortin S., Brasseur K., Leblanc V., Asselin É. and Bérubé G. (2015), New testosterone derivatives as semi-synthetic anticancer agents against prostate cancer: synthesis and preliminary biological evaluation, Medicinal Chemistry, 11, 1-9.
  4. Fortin S., Brasseur K., Morin N., Asselin É. and Bérubé G. (2013), New platinum(II) complexes conjugate at position 7α of 17β-acetyl-testosterone as new combi-molecules against prostate cancer: Design, synthesis, structure-activity relationships and biological evaluation, European Journal of Medicinal Chemistry, 68, 433-443.
  5. Marceau F., Bouthillier J., Houle S., Sabourin T., Fortin J.-P., Morissette G., Lodge R., Fortin S., C.-Gaudreault R., Bawolak M.-T., Koumbadinga G. A., Roy C., Charest-Morin X. and Gera L. (2013), Bradykinin receptors: agonists, antagonists, expression, signaling and adaptation to sustained stimulation, Journal of Angioedema, 1, 9-17.
  6. Fortin S. and Bérubé G. (2013), Advances in the development of hybrid anticancer drugs, Expert Opinion On Drug Discovery, 8, 1029-1047.
  7. Charest-Morin X., Fortin S., Lodge R., Roy C., Gera L., C.-Gaudreault R. and Marceau F. (2013), Inhibitory effects of cytoskeleton disrupting drugs and GDP-locked Rab mutants on bradykinin B2 receptor cycling, Pharmacological Research, 71, 44-52.
  8. Saha P., Fortin S., Leblanc V., Asselin É. and Bérubé G. (2012), Design, synthesis, cytocidal activity and estrogen receptor α affinity of doxorubicin conjugates at 16α-position of estrogen for site-specific treatment of estrogen receptor-positive breast cancers, Steroids, 77, 1113-1122.
  9. Turcotte V., Fortin S., Vevey F., Coulombe Y., Lacroix J., Côté M.-F., Masson J.-Y. and C.-Gaudreault R. (2012), Synthesis, biological evaluation and structure-activity relationships of novel substituted N-phenyl ureidobenzenesulfonate derivatives blocking cell cycle progression in S-phase and inducing DNA double-strand breaks, Journal of Medicinal Chemistry, 55, 6194-6208.
  10. Saha P., Descôteaux C., Brasseur K., Fortin S., Leblanc V., Parent S., Asselin É. and Bérubé G. (2012), Synthesis, antiproliferative activity and estrogen receptor α affinity of novel estradiol-linked platinum(II) complex analogs to carboplatin and oxaliplatin. Potential vector complexes to target estrogen-dependent tissues, European Journal of Medicinal Chemistry, 48, 385-390.
  11. Fortin S., Wei L., Moreau E., Petitclerc É., Lacroix J., Coté M.-F., P. Kotra L. and C.-Gaudreault R. (2011), Substituted phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonamides as antimitotics. Antiproliferative, antiangiogenic and antitumoral activity, and quantitative structure-activity relationships, European Journal of Medicinal Chemistry, 46, 5327-5342.
  12. Fortin S., Wei L., Moreau E., Lacroix J., Coté M.-F., Petitclerc É., P. Kotra L. and C.-Gaudreault R. (2011), Design, synthesis, biological evaluation and structure-activity relationships of substituted phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates as new tubulin inhibitors mimicking combretastatin A-4, Journal of Medicinal Chemistry, 54, 4559-4580.
  13. Trzeciakiewicz A., Fortin S., Moreau E., C.-Gaudreault R., Lacroix J., Chambon C., Communal Y., Chezal J.-M., Miot-Noirault E., Bouchon B. and Degoul F. (2011), Intramolecular cyclization of N-phenyl-N’-(2-chloroethyl)ureas leads to active N-phenyl-4,5-dihydrooxazol-2-amines alkylating β-tubulin Glu198 and prohibitin Asp40, Biochemical Pharmacology, 81, 1116-1123.
  14. Fortin S., Bouchon B., Chambon C., Lacroix J., Moreau E., Chezal J.-M., Degoul F. and C.-Gaudreault R. (2011), Characterization of the covalent binding of N-phenyl-N'-(2-chloroethyl)ureas to β-tubulin: importance of glutamic acid 198 in microtubule stability, Journal of Pharmacology and Experimental Therapeutics, 336, 460-467.
  15. Fortin S., Lacroix J., Côté M.-F., Moreau E., Petitclerc É. and C.-Gaudreault R. (2010), Quick and simple detection technique to assess the binding of antimicrotubule agents to the colchicine-binding site, Biological Procedure Online, 12, 113-117.
  16. Fortin S., Moreau E., Lacroix J., Coté M.-F., Petitclerc É. and C.-Gaudreault R. (2010), Synthesis, antiproliferative activity evaluation and structure-activity relationships of novel aromatic urea and amide analogues of N-phenyl-N’-(2-chloroethyl)ureas, European Journal of Medicinal Chemistry, 45, 2928-2937.
  17. Bawolak M.-T., Fortin S., Bouthillier J., Adam A., Gera L., C.-Gaudreault R. and Marceau F. (2009), Signaling, desensitization and downregulation of bradykinin B2 receptors: emerging properties of inactivation-resistant stimulants, British Journal of Pharmacology, 158, 1375-1386.
  18. Fortin S., Wei L., Moreau E., Labrie P., Petitclerc É., P. Kotra L. and C.-Gaudreault R. (2009), Mechanism of action of N-phenyl-N'-(2-chloroethyl)ureas in the colchicine-binding site at the interface between α-and β-tubulin, Bioorganic & Medicinal Chemistry, 17, 3690-3697.
  19. Fortin S., Labrie P., Moreau E., Wei L., P. Kotra L. and C.-Gaudreault R. (2008), A comparative molecular field and comparative molecular similarity indices analyses (CoMFA and CoMSIA) of N-phenyl-N'-(2-chloroethyl)urea targeting the colchicine-binding site as anticancer agents, Bioorganic & Medicinal Chemistry, 16, 1914-1926.
  20. Moreau E., Fortin S., Lacroix J., Patenaude A., L.C. Rousseau J. and C.-Gaudreault R. (2008), N-Phenyl-N’-(2-chloroethyl)ureas (CEUs) as potential antineoplastic agents. Part 3: Role of carbonyl group, Bioorganic & Medicinal Chemistry, 16, 1206-1217.
  21. Fortin S., Moreau E., Lacroix J., Teulade J.-C., Patenaude A. and C.-Gaudreault R. (2007), N-Phenyl-N'-(2-chloroethyl)urea analogues of combretastatin A-4: Is the N-phenyl-N'-(2-chloroethyl)urea pharmacophore mimicking the trimethoxy phenyl moiety?, Bioorganic & Medicinal Chemistry Letters, 17, 2000-2004.
  22. Fortin S., Moreau E., Patenaude A., Desjardins M., Lacroix J., L.C. Rousseau J. and C.-Gaudreault R. (2007), N-Phenyl-N′-(2-chloroethyl)ureas (CEU) as potential antineoplastic agents. Part 2: Role of ω-hydroxyl group in the covalent binding to β-tubulin, Bioorganic & Medicinal Chemistry, 15, 1430-1438.
  23. Labrie P., P. Maddaford S., Fortin S., Rakhit S., P. Kotra L. and C.-Gaudreault R. (2006), A comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) of anthranilamide derivatives that are multidrug resistance modulators, Journal of Medicinal Chemistry, 49, 7646-7660.
  24. Moreau E., Fortin S., Desjardins M., Rousseau J., Petitclerc É. and C.-Gaudreault R. (2005), Optimized N-phenyl-N’-(2-chloroethyl)ureas as potential antineoplastic agents: synthesis and growth inhibition activity, Bioorganic & Medicinal Chemistry, 13, 6703-6712.